Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib QT Interval and PK Study in Healthy Subjects
NCT02677844Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2016
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of abemaciclib in breast cancer (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Mean Time Matched Placebo-Adjusted Changes From Baseline For Fridericia's Corrected QT Interval (ΔΔQTcF). Started Feb 2016; status: completed.
02
Drugs
abemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02677844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02677844.